YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Antiviral Effect of a Combination Therapy of Amantadine/Biphenyl Dimethyl Dicarboxylate in HepG2 2.2.15

간암세포주 HepG2 2.2.15에서 아만타딘/비페닐디메칠디카르복실레이트 복합제의 항 바이러스 효과

  • Published : 2005.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

For decades, the demand for new antiviral strategies, especially in hepatitis, has increased markedly due to its devastating pathogenic outcome, In the present study, we examin ed the antiviral effect of the combination of amantadine and biphenyl dimethyl dicarboxylate (DDB) in HepG2 2.2.15, which is transfected with HBV DNA. The study demonstrated that the combination not the single treatment may have an anti-HBV effect through a synergism of antiviral, anti-inflammatory and cytoprotective activities in STAT1 ${\alpha}$, 6-16 gene, and pro-inflammatory components such as nitric oxide and IL-1${\beta}$ expression. In addition, hepatitis B surface and core gene expression were examined as a final end point for the anti-HBV activities, which was also significantly suppressed comparing to normal control (p<0.01).

Keywords

References

  1. Hoofnagle, J. H. : Hepatitis C: The clinical spectrum of disease. Hepatology 26, 15S (1997) https://doi.org/10.1002/hep.510260703
  2. Wright, M., Main, J. and Thomas, H. C. : Drug-resistant viral hepatitis. J. Infection. 41, 1 (2000) https://doi.org/10.1053/jinf.2000.0658
  3. Lai, C. L., Ratziu, V., Yuen, M .-F. and Poynard, T. : Viral hepatitis B. Lancet 362, 2089 (2003) https://doi.org/10.1016/S0140-6736(03)15108-2
  4. Fisher, K., Cheng, Y. and Tyrrell, D. : The mutation in duck hepatitis B polymerase which confers resistance to lamivudine (${\beta}$-L(-)-thiacytidine, 3TC) also confers cross-resistance to ${\beta}$-L-dideoxy-5-fluorocytidine. Hepaiology 24, A246 (1996)
  5. Witcher, J. W, Bouldinot, F. D., Baldwin, B. H., Ascenzi, M. A., Tennant, B. C., Du, J. F. and Chu, C. K : Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl) uracil in woodchucks. Antimicrob. Agents Chemother. 41, 2184 (1997)
  6. Heathcote, E., Jeffers, L. and Wright, T. : Loss of serum HBV DNA and HBeAg seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. Hepatology 28, A620 (1998) https://doi.org/10.1002/hep.510280303
  7. Yamanaka, G., Wilson, T., Innaimo, S., Bisacchi, G. S., Egli, P., Rinehart, J. K, Zahler, R and Colonno, R. J. : Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother. 43, 190 (1999)
  8. Oxford, J. S., Blasingam, B. S., Mann, A., Novelli, P. and Lambkin, R. : Treatment of epidemic and pandemic influenza with neuraminidase and M2 protein channel inhibitors. Clin. Midrobiol. Infect. 9, 1 (2003) https://doi.org/10.1046/j.1469-0691.2003.00564.x
  9. Wang, C., Takeuchi, K, Pinto, L. and Lamb, R. A. : Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J. Virol. 67, 585 (1993)
  10. Kang, K. W., Kim, Y. G., Kim, C. W. and Kim, S. G. : The antifibrogenic effect of a pharmaceutical composition of [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) Arch. Pharm. Res. 25, 655 (2002). https://doi.org/10.1007/BF02976940
  11. Kim, J. H., Mun, Y. J., Chun, H. J., Jeon, K. S., Kim, Y. O. and Woo, W. H. : Effect of biphenyl dimethyl dicarboxylate on the humoral immunosuppression by ethanol. Int. J. Immunother. 22, 906 (2000)
  12. Huber, R, Hockenjos, B. and Blum, H. E. : DDB treatment of patients with chronic hepatitis. Hepatology 39, 1732 (2004) https://doi.org/10.1002/hep.20247
  13. Joo, S. S., Won, T. J. and Lee, D. I. : Potential role of ursodeoxycholic acid in suppression of nuclear factor kappa B in microglial cell line (BV-2). Arch. Pharm. Res. 27, 954 (2004) https://doi.org/10.1007/BF02975850
  14. Guidotti, L. G., McClary, H., Loudis, J. M. and Chisari, F. V. : Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J. Exp. Med. 191, 1247 (2000) https://doi.org/10.1084/jem.191.7.1247
  15. Ramana, C. V., Gil, M. P., Schreiber; R. D. and Stark, G. R : STAT1-dependent and -independent pathways in IFN-${\gamma}$-dependent signaling. Trends Immunol. 23, 96 (2002) https://doi.org/10.1016/S1471-4906(01)02118-4
  16. Khabar, K. S. A., al-Haj, L., al-Zoghaibi, F., Marie, M., Dhalla, M., Polyak, S. J. and Williams, B. R. G. : Expressed gene cluster associated with cellular sensitivity and resistance towards anti-viral and anti-proliferative actions of interferon. J. Mol. Biol. 342, 833 (2004) https://doi.org/10.1016/j.jmb.2004.07.065
  17. Bose, S., Kar, N., Maitra, R, DiDonato, J. A. and Banerjee, A. K. : Temporal activation of NF-$_{\kappa}B$ regulates an interferonindependent innate antiviral response against cytoplasmic RNA viruses. Proc. Natl. Acad. Sci. USA 100, 10890 (2003)
  18. Tian, Z., Shen, X., Feng, H. and Gao, B. : IL-1${\beta}$ attenuates IFN-${\alpha}\;{\beta}$-induced antiviral activity and STAT1 activation in the liver: involvement of proteasome-dependent pathway. J. Immunol. 165, 3959 (2000) https://doi.org/10.4049/jimmunol.165.7.3959
  19. Biermer, M., Puro, R. and Schneider, R. J. : Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves distribution of capsid integrity through activation of NF-$_{\kappa}B$. J. Virol. 77, 4033 (2003)
  20. Lee, W. M. : Hepatitis B virus infection. N. Engl. J. Med. 337, 1733 (1997) https://doi.org/10.1056/NEJM199710023371409